Relapsed & Refractory Blood Cancers

AVM Biotechnology > Our Focus > Relapsed & Refractory Blood Cancers
AVM0703 Is As Effective Against Lymphoma As Chemotherapy with Reduced Toxicities

The figure on the left demonstrates the ability of AVM0703 preconditioning to enhance CarT reduction of melanoma tumor volume as much as chemotherapy preconditioning does.  AVM0703 is also as effective as chemotherapy as a stand-alone treatment against lymphoma.  Body weight is a typical indicator of drug toxicity and you can see on the right that our drug caused only minimal body weight loss compared to chemotherapy, which caused 30% loss and which also directly killed 18% of the subjects.

Our drug can replace chemotherapy as a direct therapy for lymphoma and some other cancers.  It can also replace chemotherapy preconditioning before stem cell transplant and CarT therapy, dramatically reducing patient toxicity.